Waverley Pharma Inc.

Equities

WAVE

CA94357L1058

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 09:30:00 2024-05-30 EDT			5-day change	1st Jan Change
0.025 ^CAD	-.--%		+25.00%	-.--%

04-30	Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Waverley Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 25, 2021 at 06:10 pm

Waverley Pharma Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CAD 359,963 compared to CAD 339,021 a year ago. Net loss was CAD 173,870 compared to CAD 182,532 a year ago.

Latest news about Waverley Pharma Inc.

Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Waverley Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-27	CI
Waverley Pharma Inc. Announces Changes to Board of Directors	11-22	CI
Waverley Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Waverley Pharma Inc. Auditor Raises 'Going Concern' Doubt	23-04-26	CI
Waverley Pharma Provides Business Update	23-03-20	MT
Waverley Pharma Provides Update on PARP-1 Inhibitor Program	23-01-11	MT
Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor Program	23-01-11	CI
Waverley Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Waverley Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-30	CI
Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
Waverley Pharma Inc. Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Waverley Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-26	CI
Waverley Pharma Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-26	CI
Waverley Pharma Announces Successful Tender Award For Pemetrexed With NHS England	21-05-27	MT
Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-25	CI
Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-26	CI
Waverley Pharma Inc. Auditor Raises 'Going Concern' Doubt	21-04-25	CI
Waverley Pharma : Awarded 2-Year Tender For Oncology Drug With NHS Scotland	21-01-18	MT
Waverley Pharma Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-26	CI
Waverley Pharma : Says U.S. Gives Tentative Approval For Pemetrexed Abbreviated New Drug Application	20-11-12	MT
Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United States	20-11-12	CI

Chart Waverley Pharma Inc.

Duration

Period

More charts

Company Profile

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted the Company an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WAVERLEY PHARMA INC.	-.--%	989K
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs